PHK
RNAM

Point72 Hong Kong’s Avidity Biosciences RNAM Stock Holding History

Point72 Hong Kong’s Portfolio RNAM Stock Details RNAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-4,804
Closed -$78K – 1360
2022
Q3 		$78K Buy
+4,804
New +$91.9K ﹤0.01% 1302
2022
Q1 		– Sell
-1,511
Closed -$36K – 2258
2021
Q4 		$36K Buy
+1,511
New +$36.1K ﹤0.01% 1425

Other funds holding RNAM

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Point72 Hong Kong's RNAM Position: Q4 2022 in Review

Point72 Hong Kong sold out of Avidity Biosciences (RNAM) in Q4 2022, closing a stake of 4,804 shares — an estimated $78K sold.

Point72 Hong Kong first reported a position in RNAM in Q4 2021 and held it in 2 quarters. The position peaked at $78K in Q3 2022. 148 funds tracked by Wall St. Rank hold RNAM as of Q4 2022.

  • Point72 Hong Kong reported no remaining Avidity Biosciences position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 4,804 Avidity Biosciences shares in Q4 2022, an estimated $78K.
  • Point72 Hong Kong first reported a position in Avidity Biosciences in Q4 2021 and held it in 2 quarters.
  • Point72 Hong Kong's Avidity Biosciences position peaked at $78K in Q3 2022.
  • 148 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.